Sign up Australia
Proactive Investors - Run By Investors For Investors

UBS cuts RELX to ‘sell’, believes earnings acceleration which drove material outperformance over last 3 years “coming to an end”

Following a 17% share price appreciation in the last three months, in part driven by a weaker pound, the Swiss bank has left its target price for RELX unchanged at 1,555p
Publishing
That is below the FTSE 100-listed publisher's current share price of 1,600p, down 3.3% on Wednesday’s close

UBS has put a dampener on shares in RELX PLC (LON:REL), downgrading its rating for the Anglo-Dutch publishing group to ‘sell’ from ‘neutral’ as they believe “an earnings acceleration which drove material outperformance over the last 3yrs is coming to an end”.

Following a 17% share price appreciation in the last three months, in part driven by a weaker pound, the Swiss bank has left its target price for the FTSE 100-listed firm unchanged at 1,555p, which is below the current share price of 1,600p, down 3.3% on Wednesday’s close.

READ: RELX issues "steady as she goes" AGM statement

In a note to clients, UBS’s analysts noted three reasons for their downgrade: “1) we forecast underlying earnings growth to decelerate from +6% in 2017 to +5% in FY18-21, 2) we see increasing structural risk to RELX's Journal business (c20% of group revs, 55% of STM); and 3) we believe RELX's valuation is full on 19x FY19E EPS with risks now firmly skewed to the downside. “

They added: “Our upside/downside spectrum shows only 6% upside with 28% downside. Further, marking RELX's divisions to listed peers suggests the stock is 7% overvalued at current prices.”

View full REL profile View Profile

Related Articles

Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.
mobile phone
Tue
The marketing group has already said profits for the full-year will be ahead of expectations despite only being halfway through its current financial year
Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use